دورية أكاديمية
Total skin electron irradiation for mycosis fungoides: failure analysis and prognostic factors.
| العنوان: | Total skin electron irradiation for mycosis fungoides: failure analysis and prognostic factors. |
|---|---|
| المؤلفون: | Tadros AA, Tepperman BS, Hryniuk WM, Peters VG, Rosenthal D, Roberts JT, Figueredo AT |
| المصدر: | International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 1983 Sep; Vol. 9 (9), pp. 1279-87. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 7603616 Publication Model: Print Cited Medium: Print ISSN: 0360-3016 (Print) Linking ISSN: 03603016 NLM ISO Abbreviation: Int J Radiat Oncol Biol Phys Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York, NY : Elsevier, Inc Original Publication: Elmsford, N. Y., Pergamon Press. |
| مواضيع طبية MeSH: | Electrons*, Mycosis Fungoides/*radiotherapy , Skin Neoplasms/*radiotherapy, Aged ; Female ; Humans ; Male ; Middle Aged ; Mycosis Fungoides/mortality ; Mycosis Fungoides/pathology ; Neoplasm Staging ; Particle Accelerators ; Prognosis ; Radiotherapy Dosage ; Skin Neoplasms/mortality ; Skin Neoplasms/pathology ; Time Factors |
| مستخلص: | From 1970 to 1980, 106 patients with mycosis fungoides received total skin electron irradiation to full tolerance. The majority received 30 Gy of 3 MeV electrons in 12 treatments over three weeks. Eighty-eight patients had received prior therapy. Fifty patients had cutaneous plaques only (T1-2N0), and 56 had more advanced disease. At five years, actuarial survival is 66.7% and disease-free survival 21.4%. The median time to relapse is 12 months; prolonged survival is seen only with complete response. Compared with more advanced stages, T1-2N0 patients have more frequent complete response (96% vs 71%) and better relapse-free survival at five years (32 vs 7%). Of 14 patients with T2 disease in continuous complete remission for from 45-113 months, only one has relapsed. This suggests that cure is possible in up to 26% of patients with T2 disease who achieve complete response. In advanced stages, complete response is more likely with doses over 25 Gy (80 vs 50%). First recurrences were predominently in sites of previous involvement. Death resulted mainly from extracutaneous dissemination or failure to induce remission. |
| تواريخ الأحداث: | Date Created: 19830901 Date Completed: 19831028 Latest Revision: 20190708 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/0360-3016(83)90258-4 |
| PMID: | 6885540 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0360-3016 |
|---|---|
| DOI: | 10.1016/0360-3016(83)90258-4 |